Novel AL-CA treatments such as venetoclax, which is a BCL2 inhibitor, belantamab-mafodotin, which is a B-cell maturation antigen inhibitor, and selinexor, which inhibits Exportin1, are being currently investigated [124]. The gene discussed is TNFRSF17; the disease is axial length measurement.